Proteomics

Dataset Information

0

Ezrin inhibition overcomes acquired resistance to vemurafenib in BRAFV600E-mutated colon cancer and melanoma cells in vitro

ABSTRACT: In spite of the advancements in targeted therapy for BRAFV600E-mutated metastatic colorectal cancer (mCRC), the development of resistance to BRAFV600E inhibition limits the response rate and durability of the treatment. Better understanding of the resistance mechanisms to BRAF inhibitors will facilitate the design of novel pharmacological strategies for BRAF-mutated mCRC. The aim of this study was to identify novel protein candidates involved in acquired resistance to BRAFV600E inhibitor vemurafenib in BRAFV600E-mutated colon cancer cells using an integrated proteomics approach. Our study suggests a role of ezrin in acquired resistance to vemurafenib in colon cancer and melanoma cells carrying BRAFV600E mutation and supports further pre-clinical and clinical studies to explore the benefits of combined BRAF inhibitors and actin-targeting drugs as a potential therapeutic approach for BRAFV600E-mutated cancers.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (human)

DISEASE(S): Colon Cancer

SUBMITTER: Antje Dittmann  

LAB HEAD: Mirela Sedic

PROVIDER: PXD042499 | Pride | 2023-08-29

REPOSITORIES: Pride

Json Xml

Dataset's files

Source:
Action DRS
20200224_002_S211433_cell_11_RKO-R.raw Raw
20200224_003_S211427_cell_5_RKO.raw Raw
20200224_004_S211430_cell_8_RKO-R.raw Raw
20200224_005_S211436_cell_14_RKO-R.raw Raw
20200224_006_S211425_cell_3_RKO.raw Raw
Items per page:
1 - 5 of 17
altmetric image

Publications

Ezrin Inhibition Overcomes Acquired Resistance to Vemurafenib in BRAFV600E-Mutated Colon Cancer and Melanoma Cells In Vitro.

Car Iris I   Dittmann Antje A   Vasieva Olga O   Bočkor Luka L   Grbčić Petra P   Piteša Nikolina N   Klobučar Marko M   Kraljević Pavelić Sandra S   Sedić Mirela M  

International journal of molecular sciences 20230817 16

Despite the advancements in targeted therapy for BRAFV600E-mutated metastatic colorectal cancer (mCRC), the development of resistance to BRAFV600E inhibition limits the response rate and durability of the treatment. Better understanding of the resistance mechanisms to BRAF inhibitors will facilitate the design of novel pharmacological strategies for BRAF-mutated mCRC. The aim of this study was to identify novel protein candidates involved in acquired resistance to BRAFV600E inhibitor vemurafenib  ...[more]

Similar Datasets

Proteomics The secretome features associated with the development of re-sistance to vemurafenib in BRAFV600E mutated colon cancer cells
2023-04-29 | PXD039766 | Pride
Transcriptomics Expression data from BRAFV600E A375 melanoma cells treated with vehicle or vemurafenib
2014-05-20 | GSE42872 | GEO
Transcriptomics Expression data from BRAFV600E A375 melanoma cells treated with vehicle or vemurafenib
2014-05-20 | E-GEOD-42872 | biostudies-arrayexpress
Transcriptomics Concomitant BCORL1 and BRAF mutations in vemurafenib-resistant melanoma cells
2018-11-27 | GSE107370 | GEO
Transcriptomics Vemurafenib acts as molecular switch in Langerhans Cell Histiocytosis
2021-09-23 | GSE175480 | GEO
Genomics Vemurafenib, BRAF inhibitor, Resistance in BRAFV600E Positive Thyroid Cancer cell lines
| PRJNA738167 | ENA
Transcriptomics Vemurafenib, BRAF inhibitor, Resistance in BRAFV600E Positive Thyroid Cancer cell lines
2023-02-16 | GSE178267 | GEO
Proteomics Interactome dynamics of RAF1-BRAF kinase monomers and dimers
2023-02-27 | PXD036792 | Pride
Transcriptomics Profiling melanoma cell line M14 treated with vemurafenib
2020-12-19 | GSE134838 | GEO
Genomics RNA-Seq analysis (long-reads) of human parental M238P and BRAF inhibitors-resistant M238R melanoma cells
2021-12-29 | GSE171882 | GEO